{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:21:34Z","timestamp":1793499694132,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Herzzentrum G\u00f6ttingen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Latent pulmonary vascular disease is a distinct feature already in the early pathophysiology of masked heart failure with preserved ejection fraction (HFpEF) and associated with reduced right ventricular (RV) functional reserve. We hypothesized that serial real-time cardiovascular magnetic resonance (CMR) imaging at rest and during exercise-stress may detect early progress in pathophysiological alterations in HFpEF. Patients presenting with exertional dyspnoea and signs of diastolic dysfunction (E\/e\u2019&gt;8, left ventricular (LV) ejection fraction\u2009&gt;\u200950%) were prospectively enrolled in the HFpEF Stress Trial (NCT03260621). Rest and exercise-stress echocardiography, CMR and right heart catheterisation were performed at baseline. Pulmonary capillary wedge pressure (PCWP) was used for classification of HFpEF (\u2265\u200915\/25mmHg at rest\/during exercise-stress) and non-cardiac dyspnoea (NCD). Repeat rest and exercise-stress CMR was performed in median 2.94 years after recruitment during which timeframe some HFpEF patients had undergone interatrial shunt device (IASD) implantation. Cardiovascular events were assessed after 4 years.Serial CMR scans were available for NCD\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200910, HFpEF\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200910 and HFpEF with IASD implantation following baseline diagnosis\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20096. RV long axis strain at rest and during exercise-stress decreased in HFpEF (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.007 for both) but neither in NCD nor HFpEF with IASD. In contrast, in NCD, an improvement in LA LAS during exercise-stress (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.028) was noted. There were no functional alterations in HFpEF patients who had undergone IASD implantation. RV functional deterioration may be a pathophysiological feature during early-stage disease progress in HFpEF. In this observational study RV functional deterioration was detected in HFpEF patients only but not patients with NCD and patients with HFpEF that were treated with IASD placement. These findings should next be explored in adequately powered future research trials.\n                    <jats:italic>Clinicaltrials.gov<\/jats:italic>\n                    : NCT03260621 (First posted date 24\/08\/2017).\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-87032-5","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T08:33:59Z","timestamp":1738571639000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Insights from serial cardiovascular magnetic resonance imaging show early progress in diastolic dysfunction relates to impaired right ventricular deformation"],"prefix":"10.1038","volume":"15","author":[{"given":"S\u00f6ren J.","family":"Backhaus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon F.","family":"R\u00f6sel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennart S.","family":"Schmidt-Schweda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelby","family":"Kutty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes T.","family":"Kowallick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Treiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Rolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Sossalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Hasenfu\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"key":"87032_CR1","unstructured":"1. McDonagh, T. A. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart J. 42, 3599\u20133726 (2021)."},{"key":"87032_CR2","doi-asserted-by":"crossref","unstructured":"2. Packer, M. et al. Effect of empagliflozin on worsening heart failure events in patients with heart failure and a preserved ejection fraction: The EMPEROR-preserved trial. Circulation; 10.1161\/CIRCULATIONAHA.121.056824 (2021).","DOI":"10.1161\/CIRCULATIONAHA.121.056824"},{"key":"87032_CR3","doi-asserted-by":"crossref","unstructured":"3. Hasenfu\u00df, G. et al. A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF). A multicentre, open-label, single-arm, phase 1 trial. The Lancet 387, 1298\u20131304 (2016).","DOI":"10.1016\/S0140-6736(16)00704-2"},{"key":"87032_CR4","doi-asserted-by":"crossref","unstructured":"4. Kaye, D. M. et al. Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction. ESC Heart Failure 6, 62\u201369 (2019).","DOI":"10.1002\/ehf2.12350"},{"key":"87032_CR5","doi-asserted-by":"crossref","unstructured":"5. Dhingra, N. K. et al. SGLT2 inhibitors and cardiac remodelling: a systematic review and meta-analysis of randomized cardiac magnetic resonance imaging trials. ESC Heart Failure 8, 4693\u20134700 (2021).","DOI":"10.1002\/ehf2.13645"},{"key":"87032_CR6","doi-asserted-by":"crossref","unstructured":"6. Fabris, E., Sinagra, G. & Anker, S. D. SGLT2-inhibitors: Should they be considered anti-remodeling drugs? Eur. J. Internal Med.\u00a0114, 42\u201344 (2023).","DOI":"10.1016\/j.ejim.2023.05.023"},{"key":"87032_CR7","doi-asserted-by":"crossref","unstructured":"7. Ravassa, S. et al. Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: Results from the Aldo-DHF trial. Eur. J. Heart Failure 20, 1290\u20131299 (2018).","DOI":"10.1002\/ejhf.1194"},{"key":"87032_CR8","unstructured":"8. Borlaug, B. A. et al. Latent pulmonary vascular disease may alter the response to therapeutic atrial shunt device in heart failure. Circulation; 10.1161\/CIRCULATIONAHA.122.059486 (2022)."},{"key":"87032_CR9","unstructured":"9. Shah, S. J. et al. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial. The Lancet; 10.1016\/S0140-6736(22)00016 \u2009\u2212\u20092 (2022)."},{"key":"87032_CR10","doi-asserted-by":"crossref","unstructured":"10. Schuster, A. et al. Concomitant latent pulmonary vascular disease leads to impaired global cardiac performance in heart failure with preserved ejection fraction. Eur. J. Heart Failure 25, 322\u2013331 (2023).","DOI":"10.1002\/ejhf.2781"},{"key":"87032_CR11","doi-asserted-by":"crossref","unstructured":"11. Daneshvar, D. et al. Diastolic dysfunction: improved understanding using emerging imaging techniques. Am. Heart J.\u00a0160, 394\u2013404 (2010).","DOI":"10.1016\/j.ahj.2010.06.040"},{"key":"87032_CR12","doi-asserted-by":"crossref","unstructured":"12. Ibrahim, E.-S. H., Dennison, J., Frank, L. & Stojanovska, J. Diastolic Cardiac Function by MRI-Imaging Capabilities and Clinical Applications. Tomography (Ann Arbor, Mich.) 7, 893\u2013914 (2021).","DOI":"10.3390\/tomography7040075"},{"key":"87032_CR13","doi-asserted-by":"crossref","unstructured":"13. Backhaus, S. J. et al. Exercise-stress real-time cardiac magnetic resonance imaging for non-invasive characterisation of heart failure with preserved ejection fraction: The HFpEF stress trial. Circulation 143, 1484\u20131498 (2021).","DOI":"10.1161\/CIRCULATIONAHA.120.051542"},{"key":"87032_CR14","doi-asserted-by":"crossref","unstructured":"14. Kramer, C. M. et al. Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update. J. Cardiovasc. Magn. Resonan. 22, 17 (2020).","DOI":"10.1186\/s12968-020-00607-1"},{"key":"87032_CR15","doi-asserted-by":"publisher","unstructured":"15. Backhaus, S. J. et al. Real-time cardiovascular magnetic resonance imaging for non-invasive characterisation of heart failure with preserved ejection fraction: Final outcomes of the HFpEF stress trial. Clini. Res. Cardiol., https:\/\/doi.org\/10.1007\/s00392-023-02363-5 (2024).","DOI":"10.1007\/s00392-023-02363-5"},{"key":"87032_CR16","doi-asserted-by":"crossref","unstructured":"16. Schuster, A. et al. Left atrial function with MRI enables prediction of cardiovascular events after myocardial infarction. Insights from the AIDA STEMI and TATORT NSTEMI Trials. Radiology 293, 292\u2013302 (2019).","DOI":"10.1148\/radiol.2019190559"},{"key":"87032_CR17","doi-asserted-by":"crossref","unstructured":"17. Schuster et al. Impact of right atrial physiology on heart failure and adverse events after myocardial infarction. JCM 9, 210 (2020).","DOI":"10.3390\/jcm9010210"},{"key":"87032_CR18","doi-asserted-by":"crossref","unstructured":"18. Backhaus, S. J. et al. Head-to\u2010head comparison of cardiovascular MR feature tracking cine versus acquisition\u2010based deformation strain imaging using myocardial tagging and strain encoding. Magn. Reson. Med. 85, 357\u2013368 (2021).","DOI":"10.1002\/mrm.28437"},{"key":"87032_CR19","doi-asserted-by":"crossref","unstructured":"19. Schuster, A., Hor, K. N., Kowallick, J. T., Beerbaum, P. & Kutty, S. Cardiovascular magnetic resonance myocardial feature tracking: Concepts and clinical applications. Circ. Cardiovasc. imaging 9, e004077 (2016).","DOI":"10.1161\/CIRCIMAGING.115.004077"},{"key":"87032_CR20","doi-asserted-by":"crossref","unstructured":"20. Uecker, M. et al. Real-time MRI at a resolution of 20 ms. NMR Biomed. 23, 986\u2013994 (2010).","DOI":"10.1002\/nbm.1585"},{"key":"87032_CR21","doi-asserted-by":"crossref","unstructured":"21. Schuster, A. et al. Fast manual long-axis strain assessment provides optimized cardiovascular event prediction following myocardial infarction. Eur. Heart J. Cardiovasc. Imaging 20, 1262\u20131270 (2019).","DOI":"10.1093\/ehjci\/jez077"},{"key":"87032_CR22","doi-asserted-by":"crossref","unstructured":"22. Arenja, N. et al. Right ventricular long axis strain-validation of a novel parameter in non-ischemic dilated cardiomyopathy using standard cardiac magnetic resonance imaging. Eur. J. Radiol. 85, 1322\u20131328 (2016).","DOI":"10.1016\/j.ejrad.2016.04.017"},{"key":"87032_CR23","doi-asserted-by":"crossref","unstructured":"23. Ho, J. E. et al. Exercise pulmonary hypertension predicts clinical outcomes in patients with dyspnea on effort. J. Am. Coll. Cardiol. 75, 17\u201326 (2020).","DOI":"10.1016\/j.jacc.2019.10.048"},{"key":"87032_CR24","doi-asserted-by":"crossref","unstructured":"24. Borlaug, B. A. & Obokata, M. Is it time to recognize a new phenotype? Heart failure with preserved ejection fraction with pulmonary vascular disease. Eur. Heart J. 38, 2874\u20132878 (2017).","DOI":"10.1093\/eurheartj\/ehx184"},{"key":"87032_CR25","doi-asserted-by":"crossref","unstructured":"25. Borlaug, B. A., Kane, G. C., Melenovsky, V. & Olson, T. P. Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction. Eur. Heart J. 37, 3293\u20133302 (2016).","DOI":"10.1093\/eurheartj\/ehw241"},{"key":"87032_CR26","doi-asserted-by":"crossref","unstructured":"26. Park, J. J., Park, J.-B., Park, J.-H. & Cho, G.-Y. Global Longitudinal Strain to Predict Mortality in Patients With Acute Heart Failure. J. Am. College Cardiol. 71, 1947\u20131957 (2018).","DOI":"10.1016\/j.jacc.2018.02.064"},{"key":"87032_CR27","doi-asserted-by":"crossref","unstructured":"27. Obokata, M., Reddy, Y. N. V., Melenovsky, V., Pislaru, S. & Borlaug, B. A. Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction. Eur. Heart J. 40, 689\u2013697 (2019).","DOI":"10.1093\/eurheartj\/ehy809"},{"key":"87032_CR28","doi-asserted-by":"crossref","unstructured":"28. Chacon-Portillo, M. A., Acharya, T. & Janardhanan, R. Imaging in heart failure with preserved ejection fraction: insights into echocardiography and cardiac magnetic resonance imaging. Rev. Cardiovasc. Medi. 22, 11\u201324 (2021).","DOI":"10.31083\/j.rcm.2021.01.134"},{"key":"87032_CR29","doi-asserted-by":"crossref","unstructured":"29. Werther Evaldsson, A. et al. Echocardiographic right ventricular strain from multiple apical views is superior for assessment of right ventricular systolic function. Clin. Physiol. Function. Imaging 39, 168\u2013176 (2019).","DOI":"10.1111\/cpf.12552"},{"key":"87032_CR30","doi-asserted-by":"crossref","unstructured":"30. Park, S. J. et al. Impaired RV global longitudinal strain is associated with poor long-term clinical outcomes in patients with acute inferior STEMI. JACC. Cardiovasc. Imaging 8, 161\u2013169 (2015).","DOI":"10.1016\/j.jcmg.2014.10.011"},{"key":"87032_CR31","doi-asserted-by":"crossref","unstructured":"31. Aquino, G. J. et al. Computed tomographic assessment of right ventricular long axis strain for prognosis after transcatheter aortic valve replacement. Eur. J. Radiol. 149, 110212 (2022).","DOI":"10.1016\/j.ejrad.2022.110212"},{"key":"87032_CR32","doi-asserted-by":"crossref","unstructured":"32. Beyls, C. et al. Prognostic value of a new right ventricular-to-pulmonary artery coupling parameter using right ventricular longitudinal shortening fraction in patients undergoing transcatheter aortic valve replacement: A prospective echocardiography study. JCM 13 (2024).","DOI":"10.3390\/jcm13041006"},{"key":"87032_CR33","doi-asserted-by":"crossref","unstructured":"33. Yang, F. et al. The prognostic value of biventricular long axis strain using standard cardiovascular magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Int. J. Cardiol. 294, 43\u201349 (2019).","DOI":"10.1016\/j.ijcard.2019.08.010"},{"key":"87032_CR34","doi-asserted-by":"crossref","unstructured":"34. Kanagala, P. et al. Prevalence of right ventricular dysfunction and prognostic significance in heart failure with preserved ejection fraction. Int. J. Cardiovasc. Imaging 37, 255\u2013266 (2021).","DOI":"10.1007\/s10554-020-01953-y"}],"updated-by":[{"DOI":"10.1038\/s41598-025-93248-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-87032-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-87032-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-87032-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T15:38:38Z","timestamp":1741621118000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-87032-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["87032"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-87032-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,3]]},"assertion":[{"value":"23 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-025-93248-2","URL":"https:\/\/doi.org\/10.1038\/s41598-025-93248-2","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The HFpEF-Stress Trial (No. 35\/8\/15) and consecutive follow-up was approved by the local ethics committee at the University Medical Center Goettingen. All patients gave written informed consent before participation. The study was conducted according to the principles of the Helsinki Declaration.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"4090"}}